SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Adler Robert)
 

Sökning: WFRF:(Adler Robert) > Secondary Fracture ...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007114naa a2200817 4500
001oai:lup.lub.lu.se:fe76189c-cdd8-4927-a624-a356c0d920a8
003SwePub
008200403s2020 | |||||||||||000 ||eng|
0247 a https://lup.lub.lu.se/record/fe76189c-cdd8-4927-a624-a356c0d920a82 URI
0247 a https://doi.org/10.1097/BOT.00000000000017432 DOI
040 a (SwePub)lu
041 a engb eng
042 9 SwePub
072 7a art2 swepub-publicationtype
072 7a ref2 swepub-contenttype
1001 a Conley, Robert B.u Center for Medical Technology Policy4 aut
2451 0a Secondary Fracture Prevention : Consensus Clinical Recommendations from a Multistakeholder Coalition
264 1c 2020
520 a Osteoporosis-related fractures are undertreated, due in part to misinformation about recommended approaches to patient care and discrepancies among treatment guidelines. To help bridge this gap and improve patient outcomes, the American Society for Bone and Mineral Research assembled a multistakeholder coalition to develop clinical recommendations for the optimal prevention of secondary fractureamong people aged 65 years and older with a hip or vertebral fracture. The coalition developed 13 recommendations (7 primary and 6 secondary) strongly supported by the empirical literature. The coalition recommends increased communication with patients regarding fracture risk, mortality and morbidity outcomes, and fracture risk reduction. Risk assessment (including fall history) should occur at regular intervals with referral to physical and/or occupational therapy as appropriate. Oral, intravenous, andsubcutaneous pharmacotherapies are efficaciousandcanreduce risk of future fracture.Patientsneededucation,however, about thebenefitsandrisks of both treatment and not receiving treatment. Oral bisphosphonates alendronate and risedronate are first-line options and are generally well tolerated; otherwise, intravenous zoledronic acid and subcutaneous denosumab can be considered. Anabolic agents are expensive butmay be beneficial for selected patients at high risk.Optimal duration of pharmacotherapy is unknown but because the risk for second fractures is highest in the earlypost-fractureperiod,prompt treatment is recommended.Adequate dietary or supplemental vitaminDand calciumintake shouldbe assured. Individuals beingtreatedfor osteoporosis shouldbe reevaluated for fracture risk routinely, includingvia patienteducationabout osteoporosisandfracturesandmonitoringfor adverse treatment effects.Patients shouldbestronglyencouraged to avoid tobacco, consume alcohol inmoderation atmost, and engage in regular exercise and fall prevention strategies. Finally, referral to endocrinologists or other osteoporosis specialists may be warranted for individuals who experience repeated fracture or bone loss and those with complicating comorbidities (eg, hyperparathyroidism, chronic kidney disease).
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Ortopedi0 (SwePub)302112 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Orthopaedics0 (SwePub)302112 hsv//eng
7001 a Adib, Gemmau Osteoporosis Centre, Damascus4 aut
7001 a Adler, Robert A.u Hunter Holmes McGuire VA Medical Center4 aut
7001 a Åkesson, Kristina E.u Lund University,Lunds universitet,Ortopedi - klinisk och molekylär osteoporosforskning,Forskargrupper vid Lunds universitet,Orthopedics - Clinical and Molecular Osteoporosis Research,Lund University Research Groups,Skåne University Hospital4 aut0 (Swepub:lu)orto-kak
7001 a Alexander, Ivy M.u University of Connecticut4 aut
7001 a Amenta, Kelly C.u Mercyhurst University4 aut
7001 a Blank, Robert D.u Medical College of Wisconsin,Garvan Institute of Medical Research4 aut
7001 a Brox, William Timothyu University of California, San Francisco4 aut
7001 a Carmody, Emily E.u University of Rochester4 aut
7001 a Chapman-Novakofski, Karenu University of Illinois at Urbana-Champaign4 aut
7001 a Clarke, Bart L.u Mayo Clinic Minnesota4 aut
7001 a Cody, Kathleen M.u American Bone Health4 aut
7001 a Cooper, Cyrusu University of Southampton4 aut
7001 a Crandall, Carolyn J.u University of California, Los Angeles4 aut
7001 a Dirschl, Douglas R.u University of Chicago4 aut
7001 a Eagen, Thomas J.u National Council on Aging4 aut
7001 a Elderkin, Ann L.u American Society for Bone and Mineral Research4 aut
7001 a Fujita, Masakiu International Osteoporosis Foundation, Switzerland4 aut
7001 a Greenspan, Susan L.u University of Pittsburgh4 aut
7001 a Halbout, Philippeu International Osteoporosis Foundation, Switzerland4 aut
7001 a Hochberg, Marc C.u Baltimore Veterans Administration Medical Center,University of Maryland4 aut
7001 a Javaid, Muhammadu University of Oxford4 aut
7001 a Jeray, Kyle J.u Prisma Health4 aut
7001 a Kearns, Ann E.u Mayo Clinic Minnesota4 aut
7001 a King, Tobyu United States Bone and Joint Initiative (USBJI)4 aut
7001 a Koinis, Thomas F.u Duke Primary Care Oxford4 aut
7001 a Koontz, Jennifer Scottu University of Kansas,Newton Medical Center4 aut
7001 a Kužma, Martinu University Hospital in Bratislava4 aut
7001 a Lindsey, Carleenu Bristol Physical Therapy, LLC4 aut
7001 a Lorentzon, Mattiasu University of Gothenburg,Sahlgrenska University Hospital,Australian Catholic University4 aut
7001 a Lyritis, George P.u Hellenic Osteoporosis Foundation4 aut
7001 a Michaud, Laura Boehnkeu University of Texas MD Anderson Cancer Center4 aut
7001 a Miciano, Armandou Nevada Rehabilitation Institute4 aut
7001 a Morin, Suzanne N.u McGill University4 aut
7001 a Mujahid, Nadiau Brown University4 aut
7001 a Napoli, Nicolau Sapienza University of Rome,Washington University in St. Louis4 aut
7001 a Olenginski, Thomas P.u Geisinger Health System4 aut
7001 a Puzas, J. Edwardu University of Rochester Medical Center4 aut
7001 a Rizou, Stavroulau Hellenic Osteoporosis Foundation4 aut
7001 a Rosen, Clifford J.u Maine Medical Center Research Institute,Tufts University4 aut
7001 a Saag, Kennethu University of Alabama4 aut
7001 a Thompson, Elizabethu National Osteoporosis Foundation4 aut
7001 a Tosi, Laura L.u Children’s National Health System, Washington4 aut
7001 a Tracer, Howardu Agency for Healthcare Research and Quality4 aut
7001 a Khosla, Sundeepu Mayo Clinic Minnesota4 aut
7001 a Kiel, Douglas P.u Harvard University4 aut
7102 a Center for Medical Technology Policyb Osteoporosis Centre, Damascus4 org
7730 t Journal of Orthopaedic Traumag 34:4, s. 125-141q 34:4<125-141x 0890-5339
8564 u http://dx.doi.org/10.1097/BOT.0000000000001743y FULLTEXT
8564 8u https://lup.lub.lu.se/record/fe76189c-cdd8-4927-a624-a356c0d920a8
8564 8u https://doi.org/10.1097/BOT.0000000000001743

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy